Catheter Precision announces 90% procedural success rate for its VIVO non-invasive mapping system in treating scar-related ventricular tachycardia.

Catheter Precision has announced updates on its VIVO non-invasive mapping system, recently highlighted at the European Society of Cardiology meeting. A study showcased a 90% procedural success rate for patients with scar-related ventricular tachycardia. VIVO, which has FDA and CE approvals, helps identify ventricular arrhythmia origins, enhancing workflow and reducing procedure time. The company is expanding its presence in the U.S. and internationally, with over 25 centers interested in VIVO.

October 02, 2024
4 Articles